Topic
Medical Oncology
56 Podcasts • 19 Cases • 5 Courses on BackTable
Hear how experienced clinicians in Medical Oncology approach day-to-day decision-making on BackTable. Learn from podcasts, cases, and courses curated by physician content creators. Get the BackTable app to follow this Topic and hear more of the conversations that matter to your practice.
Episode # 72 • 14 Jul 2026
Optimizing Liver-Directed Interventions for Neuroendocrine Tumors
What factors come into play when deciding whether to use liver-directed therapy or systemic therapies for neuroendocrine tumors? In this episode of the BackTable Tumor Board Podcast, Dr. Lingling Du, Dr. Chih-Yi Liao, and Dr. Abdul Khan discuss the structure of a multidisciplinary tumor board and how they approach decision-making for patients with neuroendocrine tumors. The conversation explores who benefits most from liver-directed therapy, optimal timing for intervention, and the importance of individualized treatment planning.
More on Medical Oncology
Loading recent podcasts…
Tumor Board # 72
Jul 14, 2026
with Dr. Chih-Yi Liao, Dr. Abdul Khan, Dr. Lingling Du
What factors come into play when deciding whether to use liver-directed therapy or systemic therapies for...
Urology # 314
Jul 7, 2026
with Dr. Rana McKay, Dr. Emmanuel Antonarakis, Dr. Alan Tan
With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for...
30+ listens
Vascular & IR # 659
Jun 30, 2026
with Dr. Beau Toskich, Dr. Lingling Du, Dr. Tyler Sandow
How do you safely combine locoregional and systemic therapies to treat hepatocellular carcinoma (HCC) when traditional...
750+ listens
Tumor Board # 69
Jun 25, 2026
with Meredith Donahue NP, Mary Dunn NP, Dr. Vignesh Packiam
How can clinics minimize toxicity and maximize outcomes in intravesical bladder cancer treatment? In this episode of...
80+ listens
Tumor Board # 71
Jul 7, 2026
with Dr. Rana McKay, Dr. Emmanuel Antonarakis, Dr. Alan Tan
With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for...
Tumor Board # 70
Jun 30, 2026
with Dr. Chih-Yi Liao, Dr. Xavier Keutgen, Dr. Lingling Du
How do you unravel the complexity of diagnosing and managing neuroendocrine tumors, where every case demands a tailored...
40+ listens
Urology # 312
Jun 25, 2026
with Meredith Donahue NP, Mary Dunn NP, Dr. Vignesh Packiam
How can clinics minimize toxicity and maximize outcomes in intravesical bladder cancer treatment? In this episode of...
720+ listens
Tumor Board # 68
Jun 23, 2026
with Dr. Dawood Findakly, Dr. Gregory Botta
Can the latest therapies, lessons from clinical trials, and a focus on emotional support improve outcomes for patients...
110+ listens
Tumor Board Case
Jul 13, 2026
with Dr. Chih-Yi Liao, Dr. Xavier Keutgen and Dr. Lingling Du
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
Tumor Board Case
Jun 17, 2025
with Dr. Juanita Crook, Dr. Andrea Apolo and Dr. Charles Peyton
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
Tumor Board Case
Jun 17, 2025
with Dr. Juanita Crook, Dr. Andrea Apolo and Dr. Charles Peyton
Tumor Board Case
Jun 17, 2025
with Dr. Juanita Crook, Dr. Andrea Apolo and Dr. Charles Peyton
Urology Course
3 hours, 28 lessons
Tumor Board Course
2 CME/CE credits, 2.5 hours, 19 lessons
Tumor Board Course
2 CME/CE credits, 2.5 hours, 26 lessons
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.